Legend Strategy International Holdings (LSIH) 2025 Annual Results – Key Investor Takeaways

Legend Strategy International Holdings Group Company Limited (“LSIH” or “the Group”) has released its audited annual report for the year ended 31 December 2025, outlining financial performance, operational developments, and strategic initiatives. Below are the most pertinent details for shareholders and investors, including recent events with potential to impact share price.

1. Financial Performance and Position

• Net Loss Substantially Increased: The Group reported a net loss of HK\$45.38 million for 2025, worsening from the previous year. The Group’s net current liabilities and net liabilities stood at HK\$66.68 million and HK\$102.90 million respectively as of 31 December 2025.
• Capital Raising: LSIH executed two major equity fundraising activities in 2025:
  • Rights Issue in March 2025, raising net proceeds of approximately HK\$39.06 million through the issuance of 456,191,452 new shares at HK\$0.088 per share.
  • Share Placement in September 2025, raising net proceeds of approximately HK\$12.39 million via the placement of 198,840,000 new shares at HK\$0.0622 per share.

  These actions significantly increased the Group’s share capital and shareholder base.

• Cash and Cash Equivalents: The Group’s cash and cash equivalents dropped to HK\$2.44 million (down from HK\$13.86 million in 2024), raising liquidity concerns.
• Gearing Ratio: The Group’s net debt was HK\$162.19 million at year-end, with negative equity attributable to owners. The net debt-to-equity ratio is not meaningful due to the negative equity position.
• No Dividend: For the second consecutive year, no dividend was declared or paid to shareholders.

2. Business Segments and Operations

• Principal Activities: LSIH operates two main segments:
  • Accommodation Business: Including hotel operation, property facilities management, and accommodation consultancy.
  • Healthcare and Beauty Business: Focused on health and wellness services.
• Major Customer Concentration: The top five customers accounted for 45.4% of total sales, with the largest customer at 14.1%. This concentration exposes the company to revenue risks.
• Employee Cost: Total staff costs increased to HK\$17.15 million (from HK\$15.94 million), while the number of employees fell to 94 (from 100).

3. Material Events and Strategic Developments

• Post-Year-End Acquisition (Potentially Price Sensitive):
  • On 6 March 2026 (post year-end), LSIH completed the acquisition of 100% interest in AURO Hong Kong Limited for a total consideration of HK\$22 million. AURO holds a 37.5% indirect equity interest in Beisheng Biotechnology (Shenzhen) Co., Ltd. and its subsidiaries, a group specializing in strain design and fermentation process development – signaling a strategic expansion into the biotech sector.
  • As at 31 December 2025, a deposit of HK\$15 million had already been paid. The acquisition was accounted for as a business combination using the acquisition method. Final accounting is pending completion of AURO’s financials and valuation.

  This acquisition represents a major diversification and entry into the bioengineering field, which may affect the Group’s risk profile and growth prospects. Shareholders should closely monitor updates regarding the integration and financial impact of this transaction.

• Proposed Name Change: The Company announced, subject to shareholder approval, a proposed change of English name to “Biosysen Limited” and adoption of “生物系統工程有限公司” as its Chinese name. This reflects a new strategic focus towards biotechnology and life sciences.
• Proposed New Memorandum & Articles of Association: The Company plans to adopt a second amended and restated M&A to reflect changes in name, share capital, and compliance requirements.
• Expansion of Authorised Share Capital: In February 2025, the Company increased its authorised share capital from HK\$7.8 million (780m shares) to HK\$20 million (2bn shares), facilitating future fundraising and potential business expansion.

4. Risk Factors and Going Concern

• Material Uncertainty on Going Concern: The auditors highlighted significant doubt on the Group’s ability to continue as a going concern, given the large net loss, net current liabilities, net liabilities, and low cash position. The Group is relying on stringent cost controls, improved cash collection, and future fundraising to support operations.
• Market and Economic Risks: The Group’s hotel and accommodation businesses continue to face intense competition and weak demand in the PRC, compounded by macro risks such as the sluggish Chinese property market and global geopolitical tensions.
• Concentration and Credit Risk: High dependency on a few major customers and significant credit concentration in accounts receivable.

5. Corporate Governance and Other Matters

• Compliance: The Group confirms substantial compliance with Hong Kong Listing Rules and Corporate Governance Code, except for certain deviations due to practical considerations.
• No Share Buybacks or Convertible Securities: No repurchase, sale, redemption, or grant of convertible securities/options during the year.
• Auditor: HLB Hodgson Impey Cheng Limited continues as auditor since June 2020. Fees for the 2025 audit totaled HK\$935,000.
• Public Float: As of the report date, at least 25% of the Company’s issued share capital was held by the public.

6. Outlook and Strategy

• Strategic Shift: The Group appears to be pivoting from its traditional accommodation business towards biotechnology and life sciences, as reflected in its recent acquisition and proposed name change.
• Financial Health: The Group’s ability to raise funds, control costs, and execute business transformation will be crucial for its survival and future growth.

7. Potentially Price-Sensitive Triggers for Investors

• Completion of the AURO acquisition and integration into the biotech sector is the single most significant recent event and may have a material impact on future earnings and the Group’s risk/return profile.
• The proposed corporate name change signals a strategic shift that could attract new investors or alter market perception.
• Ongoing going concern risk and reliance on additional capital raising may lead to further share dilution and volatility.

Disclaimer: This article is a summary and analysis of Legend Strategy International Holdings Group Company Limited’s 2025 annual report and related announcements. It is intended for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The Group’s financial condition includes material uncertainties, and its future performance is subject to significant operational and market risks.

View LEGEND STRAT Historical chart here